Office de la Propriété Intellectuelle du Canada
Un organisme d'Industrie Canada

Canadian Intellectual Property Office
An agency of Industry Canada

CA 2446386 C 2011/02/01

(11)(21) 2 446 386

(12) BREVET CANADIEN
CANADIAN PATENT

(13) C

(86) Date de dépôt PCT/PCT Filing Date: 2002/05/06
(87) Date publication PCT/PCT Publication Date: 2002/11/14
(45) Date de délivrance/Issue Date: 2011/02/01
(85) Entrée phase nationale/National Entry: 2003/11/07
(86) N° demande PCT/PCT Application No.: US 2002/014331
(87) N° publication PCT/PCT Publication No.: 2002/089813
(30) Priorité/Priority: 2001/05/08 (US09/851,296)

(51) Cl.Int./Int.Cl. *A61K 31/5575* (2006.01), *A61K 31/19* (2006.01), *A61K 31/192* (2006.01), *A61K 31/215* (2006.01), *A61K 31/216* (2006.01), *A61P 27/02* (2006.01), *A61P 27/06* (2006.01), *C07C 405/00* (2006.01)

(72) Inventeurs/Inventors:
BURK, ROBERT M., US;
HOLOBOSKI, MARK, US;
POSNER, MARI F., US

(73) Propriétaire/Owner:
ALLERGAN, INC., US

(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : DERIVES D'ACIDES PROSTANOIQUES 3, 7 OU 3 ET 7 THIA OU OXA UTILISES COMME AGENTS PERMETTANT DE BAISSER LA TENSION INTRAOCULAIRE

(54) Title: 3, 7 OR 3 AND 7 THIA OR OXA PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE



(57) Abrégé/Abstract:
The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula (I), wherein hatched lines represent the α configuration, α triangle represents the β configuration and a dotted line represents the presence or absence of a double bond; A and B are independently selected from the group consisting of O, S and CH_2 provided that at least one of A or B is S; D represents a covalent bond or CH_2, O, S or NH; X is CO_2R, $CONR_2$, CH_2OR, $P(O)(OR)_2$, $CONRSO_2R$ $SONR_2$ or Y is O, OH, $OCOR^2$, halogen or cyano; Z is CH_2 or a covalent bond; R is H or R^2; R^1 is H, R^2, phenyl, or COR^2; R^2 is C_1-C_5 lower alkyl and R_3 is C_1-C_5 n-alkyl, C_3-C_7 cycloalkyl, phenyl, furanyl, thienyl, or substituted derivatives thereof, wherein the substituents may be selected from the group consisting of C_1-C_5 alkyl, halogen, CF_3, CN, NO_2, CO_2R and OR.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 November 2002 (14.11.2002)

PCT

(10) International Publication Number
WO 02/089813 A3

(51) International Patent Classification[7]: A61K 31/5575, 31/215, 31/216, 31/19, 31/192, A61P 27/02, 27/06

(21) International Application Number: PCT/US02/14331

(22) International Filing Date: 6 May 2002 (06.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/851,296 8 May 2001 (08.05.2001) US

(71) Applicant *(for all designated States except US)*: **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, CA 92612 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BURK, Robert, M.** [US/US]; 1337 Cerritos Drive, Laguna Beach, CA 92651 (US). **HOLOBOSKI, Mark** [US/US]; 29342 Bobolink Drive, Laguna Niguel, CA 92677 (US). **POSNER, Mari, F.** [US/US]; 27935 Hedgeline Drive, Laguna Niguel, CA 92677 (US).

(74) Agents: **BARAN, Robert, J.** et al.; c/o Allergan, Inc., 2525 Dupont Drive, Irvine, CA 92612 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: 3, 7 OR 3 AND 7 THIA OR OXA PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE







(57) Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula (I), wherein hatched lines represent the α configuration, a triangle represents the β configuration and a dotted line represents the presence or absence of a double bond; A and B are independently selected from the group consisting of O, S and CH_2 provided that at least one of A or B is S; D represents a covalent bond or CH_2, O, S or NH; X is CO_2R, $CONR_2$, CH_2OR, $P(O)(OR)_2$, $CONRSO_2R$ $SONR_2$ or Y is O, OH, $OCOR^2$, halogen or cyano; Z is CH_2 or a covalent bond; R is H or R^2; R^1 is H, R^2, phenyl, or COR^2; R^2 is C_1-C_5 lower alkyl and R_3 is C_1-C_5 n-alkyl, C_3-C_7 cycloalkyl, phenyl, furanyl, thienyl, or substituted derivatives thereof, wherein the substituents may be selected from the group consisting of C_1-C_5 alkyl, halogen, CF_3, CN, NO_2, CO_2R and OR.

WO 02/089813 A3

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

(88) Date of publication of the international search report:
27 February 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

3, 7 OR 3 AND 7 THIA OR OXA PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE

Field of the Invention

The present invention relates to 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as potent ocular hypotensives that are particularly suited for the management of glaucoma.

Background of the Invention

Description of Related Art

Ocular hypotensive agents are useful in the treatment of a number of various ocular hypertensive conditions, such as post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts.

Glaucoma is a disease of the eye characterized by increased intraocular pressure. On the basis of its etiology, glaucoma has been classified as primary or secondary. For example, primary glaucoma in adults (congenital glaucoma) may be either open-angle or acute or chronic angle-closure. Secondary glaucoma results from pre-existing ocular diseases such as uveitis, intraocular tumor or an enlarged cataract.

The underlying causes of primary glaucoma are not yet known. The increased intraocular tension is due to the obstruction of aqueous humor outflow. In chronic open-angle glaucoma, the anterior chamber and its anatomic structures appear normal, but drainage of the aqueous humor is impeded. In acute or chronic angle-closure glaucoma, the anterior chamber is shallow, the filtration angle is narrowed, and the iris may obstruct the trabecular meshwork at the entrance of the canal of Schlemm. Dilation of the pupil may push the root of the iris forward against

the angle, and may produce pupilary block and thus precipitate an acute attack. Eyes with narrow anterior chamber angles are predisposed to acute angle-closure glaucoma attacks of various degrees of severity.

Secondary glaucoma is caused by any interference with the flow of aqueous humor from the posterior chamber into the anterior chamber and subsequently, into the canal of Schlemm. Inflammatory disease of the anterior segment may prevent aqueous escape by causing complete posterior synechia in iris bombe, and may plug the drainage channel with exudates. Other common causes are intraocular tumors, enlarged cataracts, central retinal vein occlusion, trauma to the eye, operative procedures and intraocular hemorrhage.

Considering all types together, glaucoma occurs in about 2% of all persons over the age of 40 and may be asymptotic for years before progressing to rapid loss of vision. In cases where surgery is not indicated, topical b-adrenoreceptor antagonists have traditionally been the drugs of choice for treating glaucoma.

Certain eicosanoids and their derivatives have been reported to possess ocular hypotensive activity, and have been recommended for use in glaucoma management. Eicosanoids and derivatives include numerous biologically important compounds such as prostaglandins and their derivatives. Prostaglandins can be described as derivatives of prostanoic acid which have the following structural formula:



Various types of prostaglandins are known, depending on the structure and substituents carried on the alicyclic ring of the prostanoic acid skeleton. Further

classification is based on the number of unsaturated bonds in the side chain indicated by numerical subscripts after the generic type of prostaglandin [e.g. prostaglandin E_1 (PGE_1), prostaglandin E_2 (PGE_2)], and on the configuration of the substituents on the alicyclic ring indicated by α or β [e.g. prostaglandin $F_{2\alpha}$ ($PGF_{2\beta}$)].

Prostaglandins were earlier regarded as potent ocular hypertensives, however, evidence accumulated in the last decade shows that some prostaglandins are highly effective ocular hypotensive agents, and are ideally suited for the long-term medical management of glaucoma (see, for example, Bito, L.Z. Biological Protection with Prostaglandins, Cohen, M.M., ed., Boca Raton, Fla, CRC Press Inc., 1985, pp. 231-252; and Bito, L.Z., Applied Pharmacology in the Medical Treatment of Glaucomas Drance, S.M. and Neufeld, A.H. eds., New York, Grune & Stratton, 1984, pp. 477-505. Such prostaglandins include $PGF_{2\alpha}$, $PGF_{1\alpha}$, PGE_2, and certain lipid-soluble esters, such as C_1 to C_2 alkyl esters, e.g. 1-isopropyl ester, of such compounds.

Although the precise mechanism is not yet known experimental results indicate that the prostaglandin-induced reduction in intraocular pressure results from increased uveoscleral outflow [Nilsson et.al., Invest. Ophthalmol. Vis. Sci. (suppl), 284 (1987)].

The isopropyl ester of $PGF_{2\alpha}$ has been shown to have significantly greater hypotensive potency than the parent compound, presumably as a result of its more effective penetration through the cornea. In 1987, this compound was described as "the most potent ocular hypotensive agent ever reported" [see, for example, Bito, L.Z., Arch. Ophthalmol. 105, 1036 (1987), and Siebold et.al., Prodrug 5 3 (1989)].

Whereas prostaglandins appear to be devoid of significant intraocular side effects, ocular surface (conjunctival) hyperemia and foreign-body sensation have been consistently associated with the topical ocular use of such compounds, in particular $PGF_{2\alpha}$ and its prodrugs, e.g., its 1-isopropyl ester, in humans. The clinical potentials of prostaglandins in the management of conditions associated with increased ocular pressure, e.g. glaucoma are greatly limited by these side effects.

In a series of United States patents assigned to Allergan, Inc. prostaglandin esters with increased ocular hypotensive activity accompanied with no or substantially reduced side-effects are disclosed.

U.S. Patent 5,446,041 relates to certain 11-acyl-prostaglandins, such as 11-pivaloyl, 11-acetyl, 11-isobutyryl, 11-valeryl, and 11-isovaleryl $PGF_{2\alpha}$. Intraocular pressure reducing 15-acyl prostaglandins are also disclosed.

Similarly, 11,15- 9,15 and 9,11-diesters of prostaglandins, for example 11,15-dipivaloyl $PGF_{2\alpha}$ are known to have ocular hypotensive activity. See U.S. Patent 4,994,274, U.S. Patent 5,028,624 and U.S. Patent 5,034,413.

Certain 3, 7 dithiaprostanoic acid derivatives are disclosed in the following patents:

U.S. Patent 6,043, 275 to Maruyama et al; U.S. Patent 5,892,099 to Maruyama et al; EP 0 855 389; EP 0 985 663; Japanese Patent Publication 2000-1472 and Japanese Patent Publication 10—265454.

Summary of the Invention

The present invention concerns a method of treating ocular hypertension which comprises administering to a mammal having ocular hypertension a therapeutically effective amount of a compound of formula I



wherein hatched lines represent the α configuration, a triangle represents the β configuration and a dotted line represents the presence or absence of a double bond;

A and B are independently selected from the group consisting of O, S and CH_2, provided that at least one of A or B is S;

D represents a covalent bond or CH_2 , O, S or NH;

X is CO_2R, $CONR_2$, CH_2OR, $P(O)(OR)_2$, $CONRSO_2R$, $SONR_2$ or



Y is O, OH, $OCOR^2$, halogen or cyano;

Z is CH_2 or a covalent bond;

R is H or R^2;

R^1 is H, R^2 , phenyl, or COR^2;

R^2 is C_1-C_5 lower alkyl and R^3 is C_1-C_5 n-alkyl, C_3-C_7 cycloalkyl, phenyl, furanyl, thienyl, or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C_1-C_5 alkyl, halogen, CF_3, CN, NO_2, NR_2, CO_2R and OR .

In a still further aspect, the present invention relates to a pharmaceutical product, comprising

a container adapted to dispense its contents in a metered form; and

an ophthalmic solution therein, as hereinabove defined.

Finally, certain of the compounds represented by the above formula, disclosed below and utilized in the method of the present invention are novel and unobvious.

Brief Description of the Drawing Figures

FIG. 1 is a schematic of the chemical synthesis of a certain intermediate useful in the chemical synthesis of certain of the compounds of the invention.

FIG. 2 is a schematic of the chemical synthesis of certain compounds of the invention as disclosed in Examples 5 through 7.

FIG. 3 is a schematic of the chemical synthesis of certain compounds of the invention as disclosed in Examples 9 and 10.

Detailed Description of the Invention

The present invention relates to the use of 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as ocular hypotensives. The compounds used in accordance with the present invention are encompassed by the following structural formula I:

7



A preferred group of the compounds of the present invention includes compounds that have the following structural formula II:



Another preferred group includes compounds having the formula III:



In the above formulae, the substituents and symbols are as hereinabove defined.

In the above formulae:

Preferably A and B are both S.

Preferably D represents a covalent bond or is CH_2.

Preferably R is H.

Preferably R^1 is H.

Preferably R^3 is phenyl.

Preferably when D represents a covalent bond, R^3 is n-butyl or 1-propyl cyclobutyl.

Preferably Y = O.

Preferably X is CO_2R and more preferably R is selected from the group consisting of H, methyl and i-propyl.

The above compounds of the present invention may be prepared by methods that are known in the art or according to the working examples below. The compounds, below, are especially preferred representative, of the compounds of the present invention.

{3-[(1R,2S,3R)-3-Hydroxy-2-((S)-(E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl-sulfanyl]propylsulfanyl}acetic acid methyl ester,

{3-[(1R,2S,3R)-3-Hydroxy-2-((S)-(E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl-sulfanyl]propylsulfanyl}acetic acid,

{3-[(1R,2S,3R)-3-Hydroxy-2-((S)-(E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl-sulfanyl]propylsulfanyl}acetic acid isopropyl ester,

(3-{(1R,2S,3R)-3-Hydroxy-2-[(E)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentylsulfanyl}propylsulfanyl)acetic acid methyl ester,

(3-{(1R,2S,3R)-3-Hydroxy-2-[(E)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentylsulfanyl}propylsulfanyl)acetic acid,

{3-[(1R,2S,3R)-3-Hydroxy-2-((E)-3-hydroxy-4-phenylbut-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid methyl ester,

{3-[(1R,2S,3R)-3-Hydroxy-2-((E)-3-hydroxy-4-phenylbut-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid,

{3-[(1R,2S,3R)-3-Hydroxy-2-((E)-3-hydroxy-4-phenylpent-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid methyl ester and

{3-[(1R,2S,3R)-3-Hydroxy-2-((E)-3-hydroxy-4-phenylpent-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid.

Pharmaceutical compositions may be prepared by combining a therapeutically effective amount of at least one compound according to the present invention, or a pharmaceutically acceptable acid addition salt thereof, as an active ingredient, with conventional ophthalmically acceptable pharmaceutical excipients, and by preparation of unit dosage forms suitable for topical ocular use. The therapeutically efficient amount typically is between about 0.0001 and about 5% (w/v), preferably about 0.001 to about 1.0% (w/v) in liquid formulations.

For ophthalmic application, preferably solutions are prepared using a physiological saline solution as a major vehicle. The pH of such ophthalmic solutions should preferably be maintained between 6.5 and 7.2 with an appropriate buffer system. The formulations may also contain conventional, pharmaceutically acceptable preservatives, stabilizers and surfactants.

Preferred preservatives that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate. A preferred surfactant is, for example, Tween 80. Likewise, various preferred vehicles

may be used in the ophthalmic preparations of the present invention. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose and purified water.

Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.

Various buffers and means for adjusting pH may be used so long as the resulting preparation is ophthalmically acceptable. Accordingly, buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.

In a similar vein, an ophthalmically acceptable antioxidant for use in the present invention includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.

Other excipient components which may be included in the ophthalmic preparations are chelating agents. The preferred chelating agent is edentate disodium, although other chelating agents may also be used in place or in conjunction with it.

The ingredients are usually used in the following amounts:

Ingredient	**Amount (% w/v)**
active ingredient	about 0.001-5
preservative	0-0.10
vehicle	0-40
tonicity adjustor	1-10
buffer	0.01-10
pH adjustor	q.s. pH 4.5-7.5
antioxidant	as needed
surfactant	as needed
purified water	as needed to make 100%

The actual dose of the active compounds of the present invention depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan.

The ophthalmic formulations of the present invention are conveniently packaged in forms suitable for metered application, such as in containers equipped with a dropper, to facilitate the application to the eye. Containers suitable for dropwise application are usually made of suitable inert, non-toxic plastic material, and generally contain between about 0.5 and about 15 ml solution.

The invention is further illustrated by the following non-limiting Examples, which are summarized in the reaction schemes of Figures 1 through 3 wherein the compounds are identified by the same designator in both the Examples and the Figures.

Example 1

(R)-4-(*tert*-Butyldimethylsilanyloxy)cyclopent-2-enone (2).

Tetrapropylammonium perruthenate (9.4 mg, 0.027 mmol) was added to a mixture of (1S, 4R)-4-(*tert*-butyldimethylsilanyloxy)cyclopent-2-enol prepared, according to *Tetrahedron Letters*, Vol. 37, No. 18, 1996, pp. 3083-6, (118.6 mg, 0.54 mmol), 4-methylmorpholine N-oxide (94.9 mg, 0.81 mmol) and crushed 4Å sieves (270 mg) in CH_2Cl_2 (10 mL). The mixture was stirred for 30 min and was passed through a plug of silica gel with CH_2Cl_2. The filtrate was concentrated *in vacuo* to give 100 mg (86%) of the above titled compound.

Example 2

(R)-4-(*tert*-Butyldimethylsilanyloxy)-6-oxabicyclo[3.1.0]hexan-2-one (3).

Hydrogen peroxide (4.5 mL, 46.3 mmol, 30% by wt.) and 1N NaOH (46 μL, 0.046 mmol) were added to a solution of enone **2** (2.5 g, 11.5 mmol) in MeOH (30 mL) at 0° C. After stirring 1.5 h at 0° C the mixture was concentrated *in vacuo*, washed with saturated aqueous NH_4Cl and extracted with CH_2Cl_2 (3X). The combined organics were washed with brine, dried (Na_2SO_4), filtered and concentrated *in vacuo* to afford the above titled compound.

Example 3

({3-[(R)-3-(*tert*-Butyldimethylsilanyloxy)-5-oxocyclopent-1-enylsulfanyl]propyl-sulfanyl}acetic acid methyl ester (5).

The epoxide **3** prepared above was diluted with CH_2Cl_2 (30 mL), (3-mercaptopropylsulfanyl) acetic acid methyl ester **4** (1.93 g, 10.7 mmol), prepared according to Chem. Pharm. Bull. 28 (2), 1980, 558-566, was added and the solution was cooled to 0° C. Basic alumina (11.9 g) was added and the reaction mixture was warmed to room temperature. After stirring for 18 h the mixture was filtered through celite and concentrated *in vacuo*. The residue was purified by flash column chromatography (silica gel, 6:1 hex/EtOAc) to yield 3.6 g (80 %) of the above titled compound.

Example 4

(3-{(1R,2S,3R)-3-(*tert*-Butyldimethylsilanyloxy)-2-[(S)-(E)-3-(*tert*-butyldimethylsilanoxy)oct-1-enyl]-5-oxocyclopentylsulfanyl} propylsulfanyl)acetic acid methyl ester (7).

tert-Butyllithium (1.47 mL of a 1.7M solution in pentane, 2.5 mmol) was added dropwise to a solution of *tert*-butyl[(S)-1-((E)-2-iodovinyl) hexyloxy]dimethylsilane **6** (462.5 mg, 1.25 mmol) in Et_2O (6.0 mL) at –78° C. After stirring for 30 min lithium 2-thienylcyanocuprate (6.0 mL of a 0.25M solution in THF, 1.5 mmol) was added and the reaction was stirred an additional 30 min at -78° C. A solution of enone 5 (430 mg, 1.1 mmol) in Et_2O (1 mL) was added and stirring was continued for an additional 1 h. The reaction mixture was then quickly poured into saturated aqueous NH_4Cl cooled to 0° C. The mixture was extracted with EtOAc and the organic portion was washed with brine, dried (Na_2SO_4), filtered and concentrated *in vacuo*. The residue was quickly purified by flash column chromatography (silica gel, 100% hexane followed by 8:1 hex/EtOAc) to afford 270 mg (39%) of the above titled compound.

Example 5

{3-[(1R,2S,3R)-3-Hydroxy-2-((S)-(E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl-sulfanyl]propylsulfanyl}acetic acid methyl ester (8).

Hydrogen fluoride-pyridine (220 μL) was added to a solution of *bis*-TBDMS ether 7 (70 mg, 0.11 mmol) in CH_3CN (2.0 mL) at 0° C. The reaction was warmed to room temperature, stirred 1 h, and recooled to 0° C. The reaction was quenched with saturated aqueous $NaHCO_3$ until gas evolution ceased. The mixture was extracted with CH_2Cl_2 (4X). The combined organics were washed with brine, dried (Na_2SO_4), filtered and concentrated *in vacuo*. Purification of the residue by flash column chromatography (silica

gel, 100% CH_2Cl_2 followed by 30:1 CH_2Cl_2:MeOH) provided 40 mg (90%) of the above titled compound.

Example 6

{3-[(1R,2S,3R)-3-Hydroxy-2-((S)-(E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl-sulfanyl]propylsulfanyl}acetic acid (9).

Methyl ester **8** (50 mg, 0.124 mmol) was dissolved in CH_3CN (10 μL) and pH 7.2 phosphate buffer (3.0 mL) was added. The mixture was treated with PLE (400 μL, 1.34 μmol/μL) and stirred for 16 h at 23 °C. The reaction mixture was extracted with EtOAc (3X). The combined organics were washed with brine, dried (Na_2SO_4), filtered and concentrated *in vacuo*. Purification of the residue by flash column chromatography (silica gel, 100% EtOAc) gave 5.3 mg (11%) of the above titled compound.

Example 7

{3-[(1R,2S,3R)-3-Hydroxy-2-((S)-(E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl-sulfanyl]propylsulfanyl}acetic acid isopropyl ester (10).

Isopropyl-*p*-tolyltriazene (200 μL) was added dropwise to a solution of carboxylic acid **9** (10.5 mg, 0.026 mmol) in acetone (5.0 mL) at 23 °C. After stirring for 1 h the reaction was quenched with 1N HCl and the solvent was removed *in vacuo*. The residue was extracted with CH_2Cl_2 (2X). The combined organics were dried (Na_2SO_4), filtered and concentrated *in vacuo*.

Purification of the residue by flash column chromatography (silica gel, 4:1 hex/EtOAc) gave 4.3 mg (38%) of the above titled compound.

Example 8

(3-{(1R,2S,3R)-3-(*tert*-Butyldimethylsilanyloxy)-2-[(E)-4-(*tert*-butyldimethyl-silanoxy)-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentylsulfanyl}propyl-sulfanyl)acetic acid methyl ester (12).

According to the procedure described above in Example 4, 150 mg (29%) of the above titled compound was prepared employing enone **5** (303 mg, 0.775 mmol) and *tert*-butyl-[(E)-4-iodo-1-(1-propylcyclobutyl)but-3-enyloxy]dimethylsilane **11** (328 mg, 0.777 mmol).

Example 9

(3-{(1R,2S,3R)-3-Hydroxy-2-[(E)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentylsulfanyl}propylsulfanyl)acetic acid methyl ester (13).

According to the procedure described above in Example 5, 7.9 mg (40%) of the above titled compound was prepared from enone **12** (30 mg, 0.045 mmol).

Example 10

(3-{(1R,2S,3R)-3-Hydroxy-2-[(E)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentylsulfanyl}propylsulfanyl)acetic acid (14).

According to the procedure described above in Example 6, 4.1 mg (42%) of the above titled compound was prepared from ester **13** (10 mg, 0.023 mmol).

Example 11

(3-{(1R,2S,3R)-3-(*tert*-Butyldimethylsilanyloxy)-2-[(E)-3-(*tert*-butyldimethylsilanoxy)-4-phenylbut-1-enyl]-5-oxocyclopentylsulfanyl} propylsulfanyl)acetic acid methyl ester (H).

(3-{(1R,2S,3R)-3-(*tert*-Butyldimethylsilanyloxy)-2-[(E)-3-(*tert*-butyldimethylsilanoxy)-4-phenylbut-1-enyl]-5-oxocyclopentylsulfanyl} propylsulfanyl)acetic acid methyl ester (L).

The named compound is prepared by substituting *tert*-butyl-((E)-3-iodo-1-phenyl-methylallyloxy)dimethylsilane for *tert*-butyl[(S)-1-((E)-2-iodovinyl) hexyloxy]dimethylsilane in the method of Example 4. FCC gives a higher Rf compound and a lower Rf compound, designated as H and L, respectively.

Example 12(H)

{3-[(1R,2S,3R)-3-Hydroxy-2-((E)-3-hydroxy-4-phenylbut-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid methyl ester (H).

The named compound is prepared by repeating the method of Example 5 with the named compound of Example 11 (H) rather then the named compound of Example 4.

Example 12(L)

{3-[(1R,2S,3R)-3-Hydroxy-2-((E)-3-hydroxy-4-phenylbut-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid methyl ester (L).

The named compound is prepared by repeating the method of Example 5 with the named compound of Example 11 (H) rather then the named compound of Example 4.

Example 13(H)

{3-[(1R,2S,3R)-3-Hydroxy-2-((E)-3-hydroxy-4-phenylbut-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid (H).

The named compound is prepared by repeating the method of Example 6 with the named compound of Example 12 (H) rather than the named compound of Example 5.

Example 13(L)

{3-[(1R,2S,3R)-3-Hydroxy-2-((E)-3-hydroxy-4-phenylbut-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid (L).

The named compound is prepared by repeating the method of Example 6 with the named compound of Example 12 (H) rather than the named compound of Example 5.

Example 14

(3-{(1R,2S,3R)-3-(*tert*-Butyldimethylsilanyloxy)-2-[(E)-3-(*tert*-butyldimethylsilanoxy)-4-phenylpent-1-enyl]-5-oxocyclopentylsulfanyl}propylsulfanyl)acetic acid methyl ester (H).

(3-{(1R,2S,3R)-3-(*tert*-Butyldimethylsilanyloxy)-2-[(E)-3-(*tert*-butyldimethylsilanoxy)-4-phenylpent-1-enyl]-5-oxocyclopentylsulfanyl} propylsulfanyl)acetic acid methyl ester (L).

The named compound is prepared by substituting *tert*-butyl-((E)-3-iodo-1-phenylethylallyloxy)dimethylsilane for *tert*-butyl[(S)-1-((E)-2-iodovinyl) hexyloxy]dimethylsilane in the method of Example 4. FCC gives a higher Rf compound and a lower Rf compound, designated as H and L, respectively.

Example 15(H)

{3-[(1R,2S,3R)-3-Hydroxy-2-((E)-3-hydroxy-4-phenylpent-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid methyl ester (H).

The named compound is prepared by repeating the method of Example 5 with the named compound of Example 14 (H) rather then the named compound of Example 4.

Example 15(L)

{3-[(1R,2S,3R)-3-Hydroxy-2-((E)-3-hydroxy-4-phenylpent-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid methyl ester (L).

The named compound is prepared by repeating the method of Example 5 with the named compound of Example 14 (H) rather then the named compound of Example 4.

Example 16(H)

{3-[(1R,2S,3R)-3-Hydroxy-2-((E)-3-hydroxy-4-phenylpent-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid (H).

The named compound is prepared by repeating the method of Example 6 with the named compound of Example 15 (H) rather than the named compound of Example 5.

Example 16(L)

{3-[(1R,2S,3R)-3-Hydroxy-2-((E)-3-hydroxy-4-phenylpent-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid (L).

The named compound is prepared by repeating the method of Example 6 with the named compound of Example 15 (H) rather than the named compound of Example 5.

The effects of the compounds of this invention on intraocular pressure are also provided in the following tables. The compounds were prepared at the said concentrations in a vehicle comprising 0.1% polysorbate 80 and 10 mM TRIS base. Dogs were treated by administering 25 µl to the ocular surface, the contralateral eye received vehicle as a control. Intraocular pressure was measured by applanation pneumatonometry. Dog intraocular pressure was measured immediately before drug administration and at 6 hours thereafter.

Compounds 9 and 10 were examined and showed a pronounced ocular hypotensive effect in dogs and the glaucomatous cynomonlgus monkeys, respectively. Compound 9 at a dose of 0.1% w/v reduced the intraocular pressure (IOP) by 50% and at a dose of 0.01% w/v reduced the IOP by 45%.

The compounds of Examples 5, 6, 7, 12H, 12L, 13H, 13L, 15H, 15L and 16L are also useful in lowering elevated intraocular pressure in mammals, e.g. humans.

The compounds are subjected to in vitro testing as described below. The results are reported in the Table.

20

Example#	Structure	hEP_2	hEP_{3D}	hEP_4
12H		NA	$>10^4$	100
12L		$>10^4$	$>10^4$	25
13H		NA	NA	300
13L		2200	6500	13
15H		NA	$>10^4$	200
15L		NA		800
16L		$>10^4$	300	96

The foregoing description details specific methods and compositions that can be employed to practice the present invention, and represents the best mode contemplated. However, it is apparent for one of ordinary skill in the art that further

compounds with the desired pharmacological properties can be prepared in an analogous manner, and that the disclosed compounds can also be obtained from different starting compounds via different chemical reactions. Similarly, different pharmaceutical compositions may be prepared and used with substantially the same result. Thus, however detailed the foregoing may appear in text, it should not be construed as limiting the overall scope hereof; rather, the ambit of the present invention is to be governed only by the lawful construction of the appended claims.

CLAIMS

1. An ophthalmic solution comprising a compound represented by the general Formula I



wherein hatched lines represent the α configuration, a triangle represents the β configuration and a dotted line represents the presence or absence of a double bond;

A and B are independently selected from the group consisting of O, S and CH_2 provided that at least one of A or B is S;

D represents a covalent bond or CH_2, O, S or NH;

X is CO_2R, $CONR_2$, CH_2OR, $P(O)(OR)_2$, $CONRSO_2R$ $SONR_2$ or



;

Y is O, OH, $OCOR^2$, halogen or cyano;

Z is CH_2 or a covalent bond;

R is H or R^2;

R^1 is H, R^2 , phenyl, or COR^2;

R^2 is C_1-C_5 lower alkyl and R^3 is substituted or unsubstituted furanyl or thienyl, wherein the substituents are selected from the group consisting of C_1-C_5 alkyl, halogen, CF_3, CN, NO_2, NR_2, CO_2R and OR in admixture with a non-toxic, ophthalmically acceptable liquid vehicle .

2. A pharmaceutical product, comprising a container adapted to dispense the contents of said container in metered form; and an ophthalmic solution according to claim 1 in said container.

3. Use for treating ocular hypertension or glaucoma in an animal of a therapeutically effective amount of a compound represented by the general formula I:

wherein hatched lines represent the α configuration, a triangle represents the β configuration and a dotted line represents the presence or absence of a double bond;

A and B are independently selected from the group consisting of O, S and CH_2, provided that at least one of A or B is S;

D represents a covalent bond or CH_2 , O, S or NH;

X is CO_2R, $CONR_2$, CH_2OR, $P(O)(OR)_2$, $CONRSO_2R$, $SONR_2$ or



Y is O, OH, $OCOR^2$, halogen or cyano;

Z is CH_2 or a covalent bond;

R is H or R^2;

R^1 is H, R^2 , phenyl, or COR^2;

R^2 is C_1-C_5 lower alkyl and R^3 is substituted or unsubstituted furanyl or thienyl, wherein the substituents are selected from the group consisting of C_1-C_5 alkyl, halogen, CF_3, CN, NO_2, NR_2, CO_2R and OR .

4. Use, in the manufacture of a medicament, for treating ocular hypertension or glaucoma in an animal of a therapeutically effective amount of a compound represented by the general formula I:



wherein hatched lines represent the α configuration, a triangle represents the β configuration and a dotted line represents the presence or absence of a double bond;

A and B are independently selected from the group consisting of O, S and CH_2, provided that at least one of A or B is S;

D represents a covalent bond or CH_2 , O, S or NH;

X is CO_2R, $CONR_2$, CH_2OR, $P(O)(OR)_2$, $CONRSO_2R$, $SONR_2$ or



Y is O, OH, $OCOR^2$, halogen or cyano;

Z is CH_2 or a covalent bond;

R is H or R^2;

R^1 is H, R^2 , phenyl, or COR^2;

R^2 is C_1-C_5 lower alkyl and R^3 is substituted or unsubstituted furanyl or thienyl, wherein the substituents are selected from the group consisting of C_1-C_5 alkyl, halogen, CF_3, CN, NO_2, NR_2, CO_2R and OR .

5. The use according to claim 3 or 4, wherein said compound is represented by the general formula II:



6. The use according to claim 5, wherein said compound is represented by the general formula III:



7. The use of claim 3 or 4, , wherein A and B are both S.

8. The use of claim 3 or 4, wherein D represents a covalent bond or is CH_2.

9. The use of claim 3 or 4, wherein X is CO_2 R.

10. The use of claim 9, wherein R is selected rom the group consisting of H, methyl and i-propyl.

11. The use of claim 3 or 4, wherein R is H.

12. The use of claim 3 or 4, wherein R^1 is H.

13. The use of claim 3 or 4, wherein D represents a covalent bond.


TPAP
NMO, 4A SIEVES
1 HR. 0°C TO rt
HOOH,
MeOH,
NaOH,
1.5 HR, 0°C
BASIC ALUMINA
CH_2Cl_2, 18 HRS.
0°C TO rt
TBSO
HO
HS
OCH_3
1
2
3
4
5

FIG. 1.


1. t-BuLi, THF
-78°C, 30 MIN.
2. Cu(CN)LI
-78°C, 30 MIN.
3.
-78°C, 1 HR.
PLE
PHOSPHATE BUFFER
23°C, 16 HR.
HF-PYRIDINE
CH3CN, 23°C 3 HR.
ACETONE, 23°C
1
2
3
4
5
6
7
8
9
10

FIG. 2.


1. t-BuLi, THF
-78°C, 30 MIN.
2. Cu(CN)LI
-78°C, 30 MIN.
3.
TBDMSO
-78°C, 1HR.
11
12
HF-PYRIDINE
CH3CN, 23°C 3HR.
13
PLE
PHOSPHATE BUFFER
23°C, 16 HR.
14

FIG. 3.


1. t-BuLi, THF
-78°C, 30 MIN.
2. Cu(CN)Li
-78°C, 30 MIN.
3.
-78°C, 1 HR.
6
7
HF-PYRIDINE
CH3CN, 23°C 3 HR.
8
PLE
PHOSPHATE BUFFER
23°C, 16 HR.
9
ACETONE, 23°C
10